Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma.
about
Diagnosis and treatment of bone disease in multiple myeloma: spotlight on spinal involvementIdentification of secreted proteins that mediate cell-cell interactions in an in vitro model of the lung cancer microenvironment.The Role of PI3K Isoforms in Regulating Bone Marrow Microenvironment Signaling Focusing on Acute Myeloid Leukemia and Multiple Myeloma.Current developments in salivary diagnostics.Plasma cytokine concentrations indicate that in vivo hormonal regulation of immunity is altered during long-duration spaceflight.A multiplex panel of plasma markers of immunity and inflammation in classical kaposi sarcoma.Differential expression of immunologic proteins in gingiva after socket preservation in mini pigs.Patient-Specific Variations in Biomarkers across Gingivitis and Periodontitis.Bone remodeling-associated salivary biomarker MIP-1α distinguishes periodontal disease from health.Effects of parathyroid hormone-related protein and macrophage inflammatory protein-1α in Jurkat T-cells on tumor formation in vivo and expression of apoptosis regulatory genes in vitroGlycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease.Targeted salivary biomarkers for discrimination of periodontal health and disease(s)CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone diseaseEnvironment-mediated drug resistance in Bcr/Abl-positive acute lymphoblastic leukemiaChemokines CCL2, 3, 14 stimulate macrophage bone marrow homing, proliferation, and polarization in multiple myeloma.C-C motif ligand 11 reduction in CLL patients serum after vitamin D supplementationNovel anti-myeloma agents and angiogenesis.HIV Infection and Compromised Mucosal Immunity: Oral Manifestations and Systemic Inflammation.Biological aspects of angiogenesis in multiple myeloma.Role of decorin in multiple myeloma (MM) bone marrow microenvironment.Macrophage inflammatory protein 1 alpha (MIP-1α) may be associated with poor outcome in patients with extranodal NK/T-cell lymphoma.Adipose, Bone, and Myeloma: Contributions from the Microenvironment.A peculiar molecular profile of umbilical cord-mesenchymal stromal cells drives their inhibitory effects on multiple myeloma cell growth and tumor progressionEmerging treatment approaches for myeloma-related bone disease.Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis.The MIP-1α autocrine loop contributes to decreased sensitivity to anticancer drugs.Pathogenesis of bone disease in multiple myeloma: from bench to bedside.Does combined therapy of curcumin and epigallocatechin gallate have a synergistic neuroprotective effect against spinal cord injury?Cytokine evaluation in untreated and radioimmunotherapy-treated tumors in an immunocompetent rat model.The Biological Activities of Oleocanthal from a Molecular Perspective.
P2860
Q27011865-A988958C-44F0-4182-A692-AFA9897B1DC2Q30438758-4CC35E9A-0BF0-4394-8E40-4E9C3DBDC071Q33607950-15FB2E74-D937-4FB8-8542-F01231269C82Q33803001-991B5AED-2083-4EF4-B400-FD001F0AA2ECQ34294091-73228E82-3FE1-4141-AFCC-5E1685DA9F69Q35102683-6FD5AF02-8628-4EB5-876B-2EB65CCD150AQ35596723-CBFFAC97-66B3-4F8D-A1ED-1754E4428A9EQ35788448-F7E460E7-8ECF-438F-9B29-73FA2F13D135Q35798517-A103EB0D-0AB8-4982-A4F8-DF3C75A8E522Q35857559-AA202FBC-90BE-48EE-9E79-ECD7BBBE5C80Q35899430-B1CF6ECA-111B-45DE-B598-D81AF294A0A7Q35969981-DC9056B3-F232-45EF-9854-BF007992C4F5Q36177928-7BD2CC44-AA55-4B38-BB01-A3C3E7ADA2CDQ36194829-B0B7C897-8500-41CA-A42A-3024E7763797Q36414426-2D8E122E-A2F6-435E-8D5E-E0982BB397C3Q37125164-717BE05F-D493-4569-BA59-D914081B50BBQ37132903-D16ABEF2-4C50-4E0C-A508-3921866D2A6BQ37683137-1EB1B806-D30B-4A72-815E-2C31D921D817Q37956524-47002F2B-08AA-4177-9714-FD7DE46515ABQ38302987-2B4275B4-F656-4EB2-AF75-271718ED43CFQ38381902-B9C8451D-4CEA-41B5-93CD-D3FE6EAB18E5Q38876521-7BDE0A30-3ED3-47A2-8624-51513F197E16Q39030703-477C95C9-6AFE-4F36-9618-50066C9869E0Q39090721-23DF1AD9-49B2-4E30-B4BF-CF8B45908A6CQ46898670-84A3B4D5-C107-47EF-80FB-A709D50CA09EQ47618731-B72DF0AA-CA9B-453D-9D53-68A5B9C0C2C3Q47734632-2C396EDB-87F8-4C61-AF82-06A7642F475BQ49939690-234F6823-7B77-4798-A1E8-8FC98A59F7E8Q51070198-2BFC05D0-3265-4860-8F24-A6BAE3FE376AQ53397945-1B644729-E5D0-4419-B871-E27445ABDCE9
P2860
Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma.
@ast
Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma.
@en
type
label
Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma.
@ast
Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma.
@en
prefLabel
Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma.
@ast
Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma.
@en
P2093
P2860
P1433
P1476
Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma.
@en
P2093
Amin Rahemtulla
Evangelos Terpos
Marianna Politou
Nora Viniou
P2860
P304
P356
10.1080/10428190500175049
P577
2005-12-01T00:00:00Z